{"id":"W4397007022","doi":"10.1016/j.esmoop.2024.103282","title":"261TiP TROPION-Breast05: Phase (Ph) III study of datopotamab deruxtecan (Dato-DXd) ± durvalumab (D) vs chemotherapy (CT) + pembrolizumab (pembro) in patients (pts) with PD-L1+ locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Durvalumab; Medicine; Chemotherapy; Metastatic melanoma; Docetaxel; Internal medicine; Oncology; Radiology; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005828113,0.0006686035,0.001416205,0.0004548067,0.0001747937,0.0002106711,0.0007436011,0.00008657663,0.00446739],"category_scores_gemma":[0.00004567673,0.0004554846,0.0001685886,0.001654603,0.0002396953,0.0006637625,0.0002053859,0.0005734742,0.0000208658],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009385463,"about_ca_system_score_gemma":0.001781699,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.03314261,"about_ca_topic_score_gemma":0.0162644,"domain_scores_codex":[0.9957022,0.0003935433,0.001193258,0.001102712,0.0009171512,0.000691119],"domain_scores_gemma":[0.9980109,0.0001637393,0.0003510588,0.0008821746,0.0003357575,0.0002563251],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5100307,0.02438518,0.02787041,0.001032512,0.00538512,0.001034245,0.01376991,0.00008178585,0.0003244002,0.00005313948,0.006159568,0.4098731],"study_design_scores_gemma":[0.5110927,0.03829278,0.4086646,0.007497397,0.001818442,0.0007919291,0.01016919,0.003321268,0.003465872,0.00008628256,0.01268168,0.0021179],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9898342,0.0006298688,0.00009920255,0.001048845,0.0004619588,0.006785533,0.0004661197,0.00007900492,0.0005952487],"genre_scores_gemma":[0.9956026,0.0004504707,0.0003229284,0.0004698569,0.00008474581,0.000843531,0.0001682382,0.0001390996,0.001918546],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4077552,"threshold_uncertainty_score":0.9997897,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0240032643173013,"score_gpt":0.335595626129557,"score_spread":0.3115923618122557,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}